ABL Texcell Diagnostics SA (EPA:ABLD)

Market Cap	35.35M -51.2%
Revenue (ttm)	10.53M +69.0%
Net Income	1.98M +326.8%
EPS	n/a
Shares Out	16.07M
PE Ratio	17.88
Forward PE	n/a
Dividend	0.11 (5.00%)
Ex-Dividend Date	Jul 3, 2026

Volume	4,110
Open	2.240
Previous Close	2.200
Day's Range	2.120 - 2.260
52-Week Range	2.100 - 5.000
Beta	-0.57
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 9, 2026

About ABL Texcell Diagnostics

ABL Texcell Diagnostics SA provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S RNA, hepatitis-B Virus (HBV), cytomegalovirus (CMV), herpes simplex virus (HSV), BK virus (BKV), human papillomavirus (HPV), respiratory syncytial virus (R...

• Industry: Health Information Services
• Sector: Healthcare
• CEO: Chalom Sayada
• Employees: 22
• Stock Exchange: Euronext Paris
• Ticker Symbol: ABLD

Financial Performance

In 2025, ABL Texcell Diagnostics's revenue was 7.97 million, an increase of 35.71% compared to the previous year's 5.87 million. Earnings were 986,693, an increase of 246.00%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 2, 2026

Data Sources Report a data error